Headline March 02, 2018/ INDIA AND PAKISTAN : ''ONE SPOONFUL A.I.''




Need to be administered at least one-tea-spoonful of ''Artificial Intelligence''. And some need to be administered at least one tea spoonful of Artificial Intelligence 3 times a day. Preferably 30 minutes before any meal.

YOU can think of it as a World Cup of bio-chemical research............

And with that, I and the Founders of  The World Students Society, stop and give a standing ovation to Proud Pakistan's top leadership, for handling of the crisis, up to the point.

The President, O'' Captain, Prime Minister Imran Khan, The Armed Forces all, and to the ever suffering people of Kashmir. We enclose our prayers and best wishes for peace in the world.

Every two years, hundreds of scientists enter a global competition. Tackling a biological puzzle they call ''the protein folding problem,'' they try to predict the three-dimensional shape of proteins in the human body.

No one knows how to solve the problem. Even the winners only chip away at it.  But a solution could streamline the way scientists create new medicines and fight disease.

Mohammed AIQuraishi, a biologist who has dedicated his career to this kind of research, flew in early December to Cancun, Mexico, where academics were gathering to discuss the results of the latest contest.

As he checked into his hotel, a five-star resort on the Caribbean, he was consumed by melancholy.

The contest, the Critical Assessment of Structure Prediction was not won by academics. It was won by DeepMind, the artificial lab owned by Aplhabet, Google's parent company.

''I was surprised and deflated,'' said Dr. AiQuraishi, a researcher at  Harvard Medical School. ''They were way out in front of everyone else.''

DeepMind specializes in ''deep learning,'' a type of artificial intelligence that is rapidly changing drug discovery science.

A growing number of companies are applying similar methods to other parts of the long, enormously complex process that produces new medicines.

These A.I. techniques can speed up many aspects of drug discovery and, in some cases, perform tasks typically handled by scientists.

''It is not that the machines are going to replace chemists,'' said Derek Lowwe, a longtime drug discovery researcher and the author of In the Pipeline, a widely read blog dedicated to drug discovery. ''It's that the chemists who use machines will replace those who don't.''

After the conference in Cancun, Dr. AiQuarishi described his experience in a blog post.

The melancholy he felt after losing to DeepMind gave way to what he called a ''a more rational assessment of the value of scientific research and progress.''

But he strongly criticized the pharmaceutical companies like Merck and  Novartis, as well as  academic community, for not keeping pace.

''The smartest and most ambitious researchers wanting to work on protein structure will look to  DeepMind for opportunities instead of Merck and Novartis,'' he wrote.

''This fact should send chills down the spine of pharma executives, but it won't, because they are clueless, rudderless and asleep at the helm.''

The big pharma companies see the situation differently. Though Merck is not exploring protein folding because its researchers believe its potential impact would be years away, it is applying deep learning to other aspects of its drug discovery process.

''We have to connect so many other dots,'' said Juan Alvarez, associate vice president of computational and structural chemistry at Merck.

The Honor and Serving of the latest Global Operational Research on A.I. and Medicines, continues. The World Students Society thanks author and researcher By Cadez Metz.

With respectful dedication to the Students, Professors and Teachers of the world. See ya all prepare for Great Global Elections and ''register'' on The World Students Society : wssciw.blogspot.com and Twitter-E-!WOW! - the Ecosystem 2011:

''' Up The A.I. '''

Good Night and God Bless

SAM Daily Times - the Voice of the Voiceless


Post a Comment

Grace A Comment!